Nephropathy and Diabetes Alasdair Mackie Consultant Physician Northern General Hospital.

Slides:



Advertisements
Similar presentations
Chronic kidney disease
Advertisements

Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
Prescribing in Chronic Renal Disease. Who has chronic renal disease (CKD)? CKD stages 1-V How common is it? Creatinine v GFR Basic Principles Scenarios.
Chronic kidney disease: [insert title here] Insert name, title, date here Insert acknowledgements here.
SLOW- COOKING THE BEANS “OR, HOW TO STOP WORRYING AND APPLY SOME LOVE TO THE KIDNEYS” AN APPROACH TO CKD SARA KATE LEVIN, MD JANUARY 2014.
General Practice Workshop This workshop was conceived and developed by Kidney Health Australia’s Kidney Check Australia Taskforce with particular thanks.
DIABETES AND THE KIDNEYS
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
DM & CKD Dr. Shahrzad Shahidi Professor of Nephrology Isfahan University of Medical Sciences.
Hypertension and chronic kidney disease in older people Dr Rick Fielding Consultant Renal Medicine Brighton & Sussex University Hospitals.
Cardiovascular Hot topics Dr Saqib Mahmud, MRCP(UK)
RENAL BLOOD TESTS WHAT DO THEY MEAN, WHERE TO GO FOR WHAT TO DO.
Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,
Chronic Kidney Disease NICE Guidelines 2008 Dr Jennifer Kuo Dr Naeema Rashid Dr Shamita Das.
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
Chronic Kidney Disease Workshop Maarten Taal Department of Renal Medicine Derby City General Hospital Derby Nephrology Research.
Chronic Kidney Disease Jacqueline Annand – CKD Nurse Mary Simpson – CKD Nurse Joyce Mackie – Pre Dialysis/Transplant liaison Sister.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Lesley Stevens MD Tufts-New England Medical Center
Everything you wanted to know about CKD SUE GILDERSLEVE RENAL NURSE SPECISLIST.
Diabetic Nephropathy Case Presentations. UA (Urine Dipstick) Use as an initial screen for all patients Negative to trace proteinuria requires further.
1 Diabetes Education Teaching Guide Kidney Health.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
RENAL DISEASE IN DIABETES
Diabetic Nephropathy Yiming Lit, M.D. May 5, 2009.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.
Risk estimation and the prevention of cardiovascular disease SIGN 97.
Diabetes and Kidney. Diabetic Kidney Normal Kidney.
Section 6: Management in primary care Particular emphasis on nurse practitioner’s role.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
If I had Chronic Kidney Disease: What would I want my Doctor to Know….. Liam Plant Department of Renal Medicine, Cork University Hospital Department of.
Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.
Standards of Medical Care for Patients with Diabetes Mellitus John Guzek, MD March 2003.
SHEFFIELD GUIDELINES: RENAL DISEASE IN DIABETES Dr Jenny Stephenson GP, Stannington Medical Centre
Diabetic Nephropathy in the Adolescent Age Group Henry Rodriguez, M.D. Associate Professor of Pediatrics Indiana University School of Medicine Director,
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
Section 5: Configuration of healthcare to manage CKD.
Section 2: Detection of CKD. What Tests Are Available? Direct GFR measurement –Inulin clearance –Radionuclides –Iohexol clearance 3 hr CrCl with Cimetidine.
Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Dietary Issues in Renal Complications Ulrich Wahl, Tamworth, 2010.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Hypertension Control and Progression of Renal Disease
CHRONIC KIDNEY DISEASE
Laboratory Testing For Cardiovascular Risk
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.
Dr.Ruba Nashawati. Diabetes  Leading cause of ESRD  30% 40%  DN  DN Risk type I = type II.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Management of progression of CKD 순천향 대학병원 신장내과 강혜란.
Section 2: Detection of CKD
The Significance of Albuminuria
Section 4: Managing progression of CKD
Section 6: Management in primary care
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
Multimorbidity and diabetes - what to do?
Estimated GFR in Diabetes
Diabetes Health Status Report
MANAGING KIDNEY DISEASE IN PRIMARY CARE
Recent studies of ACE inhibition in renal disease
Section 5: Configuration of healthcare to manage CKD
Goals & Guidelines A summary of international guidelines for CHD
Multimorbidity and diabetes - what to do?
Presentation transcript:

Nephropathy and Diabetes Alasdair Mackie Consultant Physician Northern General Hospital

Topics to be covered Metformin use in renal impairment Microalbuminuria The importance of the CKD classification in Diabetes and Renal Disease

Prevalence of nephropathy in Diabetes Mellitus Type 1Type 2 Prevalence –Micro-alb (%) 16 (9-21)38 (15-60) –Overt proteinuria (%) 15 (18-22)15 (5-48) –At diagnosis (%) zero9 (5-20) Annual incidence –Overt proteinuria (%) 1.2 (0 – 3)1.5 (1 – 2) 25 yr incidence (%) 25 (18-34)28(25-47)

Case study 1 A 62 year-old lady with Type 2 DM for 12 years. Well controlled HbA1c of 7.2% on a combination of Gliclazide 80 mg bd and Metformin 1g bd. Also suffers from Hypertension, IHD and ‘empty sella’ syndrome. On Ramipril 10 mg, Bendro-fluomethazide 2.5 mg and Thyroxine 50 μg per day. Renal function has been gradually deteriorating over two years with serum creatinine now 142 μmol/L. eGFR 48. You stop her Metformin and her HbA1c rises to 10.3% over the next six months. What would you do now? When should we withdraw Metformin?

When would you stop Metformin? Serum Creatinine –100 μmol/L –130 –150 –180 –200 eGFR –Proteinuria and >60 –45 to 60 –30 to 45 –15 to 30 –15 or less

Current Clinical Practice Serum Creatinine –Around 130 to 150 μmol/L eGFR –Around 45 to 60 ml/min

Remember An 80 year old lady with a SCr of 100 has an eGFR of 30 Whereas a A 50 year old man with a SCr of 200 has an eGFR of 45

ManufacturersGDABNFNICE Howlett and Bailey [NEJM 1999] Renal Function CrCl <60 SCr >107 SCr >133 CrCl <90 Heart Failure √√√ns√ Tissue Hypoxia √√√ns√ Alcohol misuse √√nsns√ Severe liver disorders √√√ns√ Contra-indications to Metformin?

MALA: the evidence Most studies demonstrate no link between Metformin and Lactate levels –Freemantle Study exception 1.86 v 1.58 mmol/L Case reports almost always where renal function severely deranged for other cause[s] DARTS-MEMO study: 1 case in 1847 patients Swedish study 1977 to 1991: 2.4 cases of lactic acidosis per patient years Cochrane database no cases with ~ patient- years exposure to Metformin.

Lothian Study of Metformin and eGFR Diabetes data-base holds [3.5%] patients Type 2 with a valid SCr measurement currently taking Metformin 2880 [25.5%] are CKD 3 [GFR <60] or worse No patients taking Metformin with CKD 4 or 5 Warren et al Diab Med [2007]

Lothian study Local practice is to withdraw Metformin when SCr > 150 If eGFR threshold set at….. ≥36 would ‘allow’ similar number to remain on Metformin and would permit use in SCr up to 180 –263 [1.3%] with SCr <150 removed –241 with SCr >150 become eligible 40 –then 560 [~3%] would have to stop treatment with Metformin –And 102 [0.5%] could start All the newly ineligible individuals female. Warren et al Diab Med [2007]

What should we do? Database of all patients on Metformin Annual test of SCr [and eGFR] Continue metformin where ≥ 60 ml/min Stop its use when eGFR ≤ 30 ml/min Review cases where eGFR 30 to 60? –Rate of decline –Other co-morbidities –More frequent monitoring Consider re-starting where eGFR improves from CKD 4

If you were 55…. And developed Type 2 Diabetes Mellitus. Fasting BS 7.6; HbA1c 8.3%. Your blood pressure was measured at 168/84, urinalysis trace protein and SCr 94 [eGFR 75]. Your serum cholesterol is 5.8 mmol/L and LDL 3.2. At Eye Screening visual acuities were 6/6 and 6/9 {R and L}. Fundoscopy – N. Would you screen your urine for albumin and if so how? What would you do with the result? Under what circumstances would you investigate for Non-diabetic Renal Disease? If you were found to have micro-albumin how tightly would you control (a)Blood sugar? (b)Blood pressure? (c)And with what agent? (d)Cholesterol? (e)What additional advice would you offer?

How do we measure microalbuminuria? ‘albustix’ - –exclude proteinuric subjects –trace/intermittent positive Micral-test strip Albumin creatinine ratio: [first morning or random] Albumin excretion rate –timed overnight collection –24-hour urine –timed ambulant collection –measured after water load [Definition: 20 to 200  g/min in 2 of 3 timed collections (~8 hours) over 3 months]

Who should be screened? Exclude subjects with proteinuria Type I –DM developed pre-pubertally - from puberty –DM developed after puberty - 5 years onwards Type II –from diagnosis – NICE recommends but ? Annual testing?

What are the difficulties? Which sample? –Random sample –First morning How many in what timescale? How do we manage the borderline samples? Could it be a false positive –Intercurrent illness –Metabolic decompensation Should we undertake timed collections? If so in whom should we undertake?

Screening for Micro-albuminuria ACR Proteinuria protocol 2+ ACR > 2.5(m) or 3.5(f) 2+ samples < 20 mg/mmol Retest in one year Incipient diabetic nephropathy Determine AER (? No. tests) >  g/min + No NDRD Pre-test for protein +ve -ve 2 more ACR +ve

Factors interfering with microalbumin screening IncreaseDecrease Poor glycaemic control ACE inhibitors FeverNSAIDs CCFMalnutrition UTI Exercise Haematuria

Classification of albumin excretion NormoalbuminMicroalbuminMacroalbumin AER (mg/24 hr) < >300 AER (μg/min) < >200 ACR (mg/mmol) Males< >25 Females< >35

To screen or not to screen? Should lead to or be: Identification of a high or higher risk group Predictable prognosis for selected subjects Intervention improves outcome Reliable, accurate and valid measure Cost effective

“To justify screening for microalbuminuria, there should be evidence that identifying patients with microalbuminuria provides a benefit in terms of an enhanced response to therapeutic interventions of improved glycaemic and BP control when compared with treating the population of people with diabetes as a whole, particularly those whose urine albumin excretion is normal” Newman et al [2005] Health Technology Assessment

Why do we measure Microalbumin? NICE recommendations Diabetes Guidelines We get paid to do so or not…. Identifies a high risk clinical group e.g. –Proliferative retinopathy –Progression to Renal disease –Vascular disease in Type 2 Diabetes Other reason[s]

Microalbumin screening Relationship of micro-albuminuria to outcome –all cause mortality/CVS mortality and CVS events [Type 1 &2] –development of proliferative retinopathy [Type 1] –development of proteinuria and ESRD [Type 1 & 2] Significant changes in microalbumin status –Significant numbers of patients regress Impact of intervention –Glycaemic control Type 1 :No evidence of benefit of improved glycaemic control Type 2 :Limited evidence in slowing decline of GFR and progression to proteinuria –Blood pressure Positive benefit in delaying progression to clinical proteinuria No consistent treatment effect of ACEi in slowing decline of GFR

Areas of uncertainty What is the benefit of screening and treatment for those individuals who are normotensive? What is the value of identifying those who remain ma +ve despite achieving target BP? Does regression of microalbuminuria reduce the risk?

Why should we not screen for microalbuminuria? Many subjects with do not show progression –Microalbuminuria Adults –Regression26% –Progression19% Adolescents –Regression44% –Progression15% –Macroalbuminuria Regression occurs but lower rates What is the added benefit of identifying and treating those with micro- as oppose to normo-alb? Risk of under treating those without micro-alb Health Technology Assessment - Newman et al. [2005]

A word about PCR Protein:creatinine ratio Units: mg protein/mmol creatinine Measured by Clinical Chemistry Measure where ‘dipstix’ positive Random urine – universal container What does it mean? –PCR of 100 equivalent to 1g in 24 hours –PCR of 50 equivalent to 500mgs in 24 hours –PCR of >30 approximates to macroalbuminuria

Consider Non-Diabetic Renal Disease In the absence of Diabetic Retinopathy Advanced renal impairment with low AER Rapid decline of eGFR Rapid rise in protein excretion or Nephrotic Syndrome Active urine sediment –Vasculitides Refractory hypertension Symptoms +/or signs of other systemic disease –Myeloma/amyloidosis –SLE –Vasculitides Marked [>30%] reduction of GFR with introduction of ACEi or ARB

Diabetes and eGFR CaseClassificationCaveats What does it mean for patients? How to deal with in practice

Case scenario 3 An 78 year old lady attends your diabetes clinic. She has had Type 2 diabetes for 4 years and is on Gliclazide 160 mg bd and Pioglitazone 15 mg. She takes Ramipril 5 mg and Amlodipine 10 mg to control her BP, together with simvastatin 20 mg and aspirin 75 mg. Her HbA1c is 8.2% and eGFR 42 ml/min. BP 154/76. 1.What is her CKD status? 2.What do you think about her renal function? 3.Are there any other tests you may wish to do? 4.What, if any, alteration[s] would you make to her treatment? 5.What else might you wish to do?

Classification of eGFR CKD 1*normal>90 ml/min CKD 2*mild60-90 CKD 3moderate30-59 CKD 4severe15-29 CKD 5end-stage or RRT<15 * Must have other evidence or renal disease, e.g proteinuria – haematuria - structural changes

Recent sub-classification CKD 3aeGFR of CKD3beGFR of suffixed with p = associated with PCR >100 e.g. CKD 2p means an eGFR of 60 to 89 with proteinuria [PCR >100] e.g. CKD 2p means an eGFR of 60 to 89 with proteinuria [PCR >100]

How do we estimate GFR? Modification of Diet in Renal Disease [MDRD] Formula: GFR{ml/min/1.73m 2 } = 175 x {SCr/88.4} x {age} x {0.742 if female} x {1.210 if AfroCaribbean}

Caveats Less accurate at higher eGFR Unrepresentative in Acute Renal Failure Less accurate in those with muscle wasting Not validated in certain groups –children –old age –pregnancy –certain racial groups Requires ‘serial’ measurements at least > 3 months to determine classification Don’t forget the clock starts ticking at 40 – GFR declines 1 ml/min/annum

What does it mean for patients? I have another ‘disease’ Increased risk of death and/or cardio- vascular disease Aggressive risk factor management More frequent attendance and monitoring Referral to hospital Review of medication – Metformin Introduction of insulin

Clinical implications Risk of Cardiovascular Death in individuals followed up for 5 years CKD 319.5%2-3-fold ↑ risk CKD 424.3% CKD 545.7% Keith et al [2004] Arch Int Med

Cardiovascular Event Rate Age-standardised rate of cardiovascular events per 100-person years CKD Stage3a3b45 Go et al 2005 GFR ml/min/1.73m 2

Address cardiovascular risk to stop them dying  Lifestyle, Diabetes, Hypertension, ACE inhibitors, Lipids Slow progression of renal disease to delay the need for dialysis  Lifestyle, Diabetes, Hypertension, ACE inhibitors, Lipids  (specific treatments) Avoid harm and be prepared!  Medicine management  Ensure timely referral and access to pre-dialysis care What is the point of knowing about patients with CKD?

Conclusions Be aware of eGFR in patients on Metformin Stop Metformin when eGFR <30 Be alert to DM patients [usually Type 2] who may have non-diabetic renal disease Always check urine for protein Consider the pros and cons of microalbumin testing Know the eGFR of your DM patients and whether declining Be aware of the guidelines for referral to the Renal Unit of your local hospital

Crude option appraisal: Microalbumin screening in Type 2 DM Option 1 Treat all with ACEi and no screening Cost: £6629 per life year gained Option 2 Screen all patients for microalbuminuria Treat only those who are positive with ACEi Cost: £15157 per life year gained Option 3 Screen all not on BP therapy Treat positives with ACEi Cost: £5745 per life year gained

Supplementary Case ZO is 16. She has had Diabetes for 4 years and until recently has had good glycaemic control with HbA1c usually <8%. Over the last 12 to 18 months control has been less good with HbA1c of 12 to 14.5%. She has had intermittent protein excretion. A recent random PCR was with two subsequent first morning levels >100. Her BP is 92/54. 1.What further information would you like to know? 2.What further assessment[s] would you make? 3. How should she be managed? 4. What guidance would you offer her in relation to managing her diabetes and protein excretion?